Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

clinical investigation of the TLR7 mechanism in HCV by taking ANA773 into a clinical trial under a two-part protocol designed to test ANA773 in both healthy volunteers and patients with HCV. In October, Anadys completed dosing in healthy volunteers. Subjects received a single dose followed by four doses taken every other day, at levels from 200 mg to 1600 mg (with six subjects receiving active and two receiving placebo in each dose cohort). No serious adverse events were reported. Biomarker induction indicative of immune activation was seen in a majority of subjects beginning at 800 mg. Some side effects commonly seen with interferon treatment, including fever and chills, were observed at higher doses, with the frequency and intensity of interferon-like side effects increasing with dose. One subject at the 1200 mg dose and two subjects at the 1600 mg dose discontinued from the trial before completion of dosing. Anadys expects to initiate Part B of the study in HCV patients within the next few weeks. Patients in the first cohort will receive 800 mg of ANA773 every other day for 28 days. Doses for subsequent cohorts will be selected based on viral load and tolerability data from the 800 mg cohort.

-- Phase I Clinical Trial of ANA773 in Oncology. Anadys continues to enroll patients in an ongoing Phase I clinical trial of ANA773 in oncology and has now completed enrollment in the third cohort.

Webcast of Conference Call

Anadys will host a conference call at 5:00 p.m. EDT today to discuss its third quarter financial results and highlights and to provide an update on its development programs. A live webcast of the call will be available online at http://www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 86226986. The webcast and t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Boston, MA (PRWEB) November 21, 2014 ... and key investors will gather on December 3rd ... Boston Biotech Conferences series. GeneticRx will take place ... Harvard Medical School and will discuss the present ... gene therapy, exon skipping, and gene editing—as well ...
(Date:11/22/2014)... On November 17th Chicago start-up Briteseed ... Medical Technologies Summit in San Francisco to take first ... among Silicon Valley investors and technology elites as the ... also positions Briteseed to move on to the ... and compete with other elite innovation finalists for a ...
(Date:11/22/2014)... element of surprise has been a major advantage of ... Until now, epidemiologists had nothing to measure that might ... suboptimal responses to both the H1N1 pandemic of 2009 ... http://photos.prnewswire.com/prnh/20141121/160242 That virus advantage ... structural changes have been found that invariably to date ...
(Date:11/21/2014)... 2014   TRU-D SmartUVC LLC and its UK ... automated disinfection robot, TRU-D SmartUVC, at FIS 2014 in ... to 26 at Stand 23. The conference, hosted ... Kingdom,s largest infection-related event of its kind and ... of the leading events of its type throughout the world. ...
Breaking Biology Technology:Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3Viruses' Advantage of Surprise is Lost 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3
... /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: CO ... blood banking operator in China, today announced the results of ... 18, 2011, in Hong Kong. At the Annual ... Chen to serve on the Board of Directors until the ...
... This release is available in French . ... amount of groundwater pollution worldwide, and this has had a negative ... Research Chair in Isotope Geochemistry of the Earth and the Environment ... part in the THINK CANADA Press Breakfast Sunday at AAAS. Her ...
... -- 3SBio Inc. (Nasdaq: SSRX ) ("3SBio" ... on researching, developing, manufacturing and marketing biopharmaceutical products, today ... the fourth quarter and the fiscal year ended December ... Tuesday, March 15, 2011 at 8:00pm (Eastern). ...
Cached Biology Technology:China Cord Blood Corporation Announces Results of 2010 Annual General Meeting 2Water, water, everywhere... but is it safe to drink? 23SBio Inc. Schedules Unaudited Fourth Quarter and Fiscal Year 2010 Results 2
(Date:11/11/2014)... Nov. 11, 2014  Forensicon, Inc., a ... pleased to announce the promotion of Yaniv Schiff ... Digital Forensics. In Schiff,s new role as Director, he ... of digital forensics examiners and provide leadership within the ... - http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined ...
(Date:11/7/2014)... Debra Auguste, associate professor, biomedical engineering, in the ... of New York, have identified a molecule that ... the most aggressive forms of breast cancer. , ... mortality rate owing to aggressive proliferation and metastasis ... Professor Auguste,s team, discovered the overexpression of intercellular ...
(Date:11/7/2014)... CORAL SPRINGS, Florida , November 6, 2014 ... improved secure authentication for better mobile security revolutionizing online transactions. ... NXTD ), Alibaba Holdings Ltd. (NYSE: BABA ), ... MSFT ), eBay Inc. (NASDAQ: EBAY ... (NASDAQ: NXTD and NXTDW), a biometric authentication ...
Breaking Biology News(10 mins):Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... A new study from the Center for Interdisciplinary ... an additional link between Light At Night (LAN) and ... carried out at the University of Haifa that also ... to ,environmental light pollution, which the study has shown ...
... is fascinating to watch the orderly and seemingly choreographed ... or insects. However, the formation and the manifold motion ... the understanding of complex systems. A team of physicists ... developed a versatile biophysical model system that opens the ...
... Purdue University researchers have developed a new type of ... "microneedles" to deliver a wider range of medications than ... patches are limited to delivering drugs that, like nicotine, ... absorbed through the skin, said Babak Ziaie, a professor ...
Cached Biology News:Connection between light at night (LAN) and cancer revealed in additional study 2A model system for group behavior of nanomachines 2A model system for group behavior of nanomachines 3New pump created for microneedle drug-delivery patch 2
... Rack inserts fit into the ... allow you to greatly increase ... deepwell format plates at an ... from the shaker at once ...
...
Mixing speed from 750-3200RPM, small vortexing orbit of1.0mm...
Request Info...
Biology Products: